Evidence map›Paper›PMID 40347428›Full record

ArticleWorld journal of pediatrics : WJP2025

Performance of EMA algorithm, 2022 ACR/EULAR criteria, and EMA-ACR/EULAR algorithm in classifying pediatric ANCA-associated vasculitis: a national cohort study in China.

Zhe Lu, Li-Wen Tan, Hong Xu, Zheng-Kun Xia, Xiao-Yun Jiang, Xiao-Chuan Wu, Fang Wang, Xiao-Rong Liu, Cheng-Guang Zhao, Xiao-Zhong Li and 10 more

Abstract readMulticenter Study
In one paragraph

Article in World journal of pediatrics : WJP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zhe LuDepartment of Nephrology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Key Laboratory of Children's Vital Organ Development and Diseases of Chongqing Health Commission, Zhongshan 2nd Rd. 136, Chongqing, 400014, China.
Li-Wen TanDepartment of Nephrology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Key Laboratory of Children's Vital Organ Development and Diseases of Chongqing Health Commission, Zhongshan 2nd Rd. 136, Chongqing, 400014, China.
Hong XuDepartment of Nephrology, Children's Hospital of Fudan University, National Pediatric Medical Center of China, Shanghai, China.
Zheng-Kun XiaDepartment of Pediatrics, Jinling Hospital, Nanjing Medical University, Nanjing, China.
Xiao-Yun JiangDepartment of Pediatric Nephrology and Rheumatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Xiao-Chuan WuDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.
Fang WangDepartment of Pediatrics, Peking University First Hospital, Beijing, China.
Xiao-Rong LiuDepartment of Nephrology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Cheng-Guang ZhaoDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Xiao-Zhong LiDepartment of Nephrology and Immunology, Children's Hospital of Soochow University, Suzhou, China.
Jian-Hua MaoDepartment of Nephrology, Children Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiao-Wen WangDepartment of Nephrology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Wen-Yan HuangDepartment of Nephrology and Rheumatology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiao-Shan ShaoPediatric Nephrology Department, Guiyang Maternal & Child Health Care Hospital, Guiyang, China.
Jian-Jiang ZhangDepartment of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shi-Pin FengDepartment of Nephrology, Chengdu Women and Children Central Hospital, Chengdu, China.
Jun YangDepartment of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China.
Qiu LiDepartment of Nephrology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Key Laboratory of Children's Vital Organ Development and Diseases of Chongqing Health Commission, Zhongshan 2nd Rd. 136, Chongqing, 400014, China.
Ai-Hua ZhangDepartment of Nephrology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, 210008, China. zhaihua@njmu.edu.cn.
Mo WangDepartment of Nephrology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Key Laboratory of Children's Vital Organ Development and Diseases of Chongqing Health Commission, Zhongshan 2nd Rd. 136, Chongqing, 400014, China. wangmo_cqmu@163.com.ORCID 0000-0003-1673-3631

Funding

the National Key R&D Program of China 2021YFC2702002
6 · The paper itself

Abstract

backgroundAnti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a type of necrotizing vasculitis with poor prognosis, which is more severe in children. Classifying AAV patients may be helpful for diagnosis and management. However, present classification criteria for pediatric AAV are developed mainly based on adults, which have limitations in clinical practice. In this study, we introduced an updated algorithm based on the European Medicines Agency (EMA) algorithm in conjunction with the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria. This new approach aims to resolve the issue of duplicate classification present in the 2022 ACR/EULAR criteria and to refine the existing EMA algorithm.

methodsThis study included 179 pediatric patients diagnosed with AAV across 17 centers in China. Patients were classified using the EMA algorithm, the ACR/EULAR criteria, and the EMA-ACR/EULAR algorithm. The Kappa value and Net Reclassification Index (NRI) were used to evaluate the classification performance of these criteria.

resultsAccording to the EMA algorithm, 136 (76.0%) patients were classified with microscopic polyangiitis (MPA) and 14 (7.8%) with granulomatosis with polyangiitis (GPA), while 29 (16.2%) remained unclassifiable. According to the ACR/EULAR criteria, 145 (81.0%) patients were classified with MPA, 14 (7.8%) with GPA, 2 (1.1%) with eosinophilic granulomatosis with polyangiitis (EGPA), and 4 (2.2%) with both MPA and GPA, while 14 (7.8%) remained unclassifiable. The EMA-ACR/EULAR algorithm classified 124 patients (69.3%) as MPA, 26 (14.5%) as GPA, and 2 (1.1%) as EGPA, while 27 (15.1%) were unclassified. The Kappa values between the EMA algorithm and ACR/EULAR criteria for GPA and MPA were 0.225 [95% confidence interval (CI) 0.000-0.456, P = 0.003] and 0.357 (95% CI 0.196-0.518, P < 0.001). Compared to these two criteria, the EMA-ACR/EULAR algorithm demonstrated positive NRIs in the classification of both GPA (0.702, 95% CI 0.258-1.146, P = 0.002; 0.547 95% CI 0.150-0.944, P = 0.007) and MPA (0.425, 95% CI 0.209-0.642, P < 0.001; 0.519, 95% CI 0.305-0.733, P < 0.001).

conclusionsThe EMA-ACR/EULAR algorithm addresses the limitations of the 1990 ACR criteria within the EMA framework and resolves the issue of duplicate classification in the 2022 ACR/EULAR criteria. However, further research is necessary to validate the superiority of the EMA-ACR/EULAR algorithm in the clinical classification of pediatric AAV patients.

Indexed as

AlgorithmsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAdolescentChildChild, PreschoolChinaCohort StudiesFemaleHumansMaleRetrospective StudiesAnti-neutrophil cytoplasmic antibody-associated vasculitisChildrenClassification criteria

Identifiers

PMID40347428
PMCPMC12103362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.